Hydroxyurea for treatment of unresectable and recurrent meningiomas. I. Inhibition of primary human meningioma cells in culture and in meningioma transplants by induction of the apoptotic pathway.
暂无分享,去创建一个
R. Fahlbusch | R. Marschalek | F. Kiesewetter | U. Schrell | M. Rittig | M. Anders | U. Koch | Rolf Marschalek | Marc Anders | Rudolf Fahlbusch | Michael G. Rittig | Franklin Kiesewetter
[1] C. Matula,et al. Meningiomas of the space of the cavernous sinus. , 1996, Neurosurgery.
[2] H. van Loveren,et al. Evidence of meningioma infiltration into cranial nerves: clinical implications for cavernous sinus meningiomas. , 1995, Journal of neurosurgery.
[3] R. Fahlbusch,et al. Inhibition of proliferation of human cerebral meningioma cells by suramin: effects on cell growth, cell cycle phases, extracellular growth factors, and PDGF-BB autocrine growth loop. , 1995, Journal of neurosurgery.
[4] R. Carroll,et al. Platelet-derived growth factor expression and stimulation in human meningiomas. , 1994, Journal of neurosurgery.
[5] O. Al-Mefty,et al. Outcome of aggressive removal of cavernous sinus meningiomas. , 1994, Journal of neurosurgery.
[6] R. Fahlbusch,et al. Meningiomas and neurofibromatosis for the oncologist. , 1994, Current opinion in oncology.
[7] V. Speirs,et al. Interleukin-6 (IL-6) production and cell growth of cultured human ameningiomas:- Interactions with interleukin-1β (IL-1β) and interleukin-4 (IL-4) in vitro , 1994, Neuroscience Letters.
[8] R. Carroll,et al. Progesterone receptor expression in meningiomas. , 1993, Cancer research.
[9] R. Strange,et al. Apoptosis in the genesis and prevention of cancer. , 1992, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[10] S. Ben‐Sasson,et al. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation , 1992, The Journal of cell biology.
[11] R. Fahlbusch,et al. Presence of dopamine D1 receptors and absence of dopamine D2 receptors in human cerebral meningioma tissue. , 1992, Journal of neurosurgery.
[12] R. Fahlbusch,et al. Growth of cultured human cerebral meningiomas is inhibited by dopaminergic agents. Presence of high affinity dopamine-D1 receptors. , 1990, The Journal of clinical endocrinology and metabolism.
[13] M. Nistér,et al. Expression of PDGF β‐receptors in human meningioma cells , 1990 .
[14] R. Fahlbusch,et al. Hormonal dependency of cerebral meningiomas. Part 1: Female sex steroid receptors and their significance as specific markers for adjuvant medical therapy. , 1990, Journal of neurosurgery.
[15] P. McL. Black,et al. Human meningiomas co‐express platelet‐derived growth factor (pdgf) and pdgf‐receptor genes and their protein products , 1990, International journal of cancer.
[16] J. Foekens,et al. Effects of progesterone on the response to epidermal growth factor and other growth factors in cultured human meningioma cells. , 1990, Cancer research.
[17] J. Maroon,et al. The management of optic nerve sheath meningiomas. , 1988, American journal of ophthalmology.
[18] W. Friedman,et al. The meningioma controversy: postoperative radiation therapy. , 1988, International journal of radiation oncology, biology, physics.
[19] M. Prados,et al. Treatment of recurrent brain stem gliomas and other central nervous system tumors with 5-fluorouracil, CCNU, hydroxyurea, and 6-mercaptopurine. , 1988, Neurosurgery.
[20] W. Wara,et al. Treatment of medulloblastoma with procarbazine, hydroxyurea, and reduced radiation doses to whole brain and spine. , 1988, Journal of neurosurgery.
[21] P. Kelly,et al. Characterization of the epidermal growth factor receptor in human meningioma. , 1987, Cancer research.
[22] N. Barbaro,et al. Radiation therapy in the treatment of partially resected meningiomas. , 1987, Neurosurgery.
[23] D. W. Beck,et al. Effect of the antiprogesterone RU-38486 on meningioma implanted into nude mice. , 1987, Journal of neurosurgery.
[24] J. Jääskeläinen,et al. Seemingly complete removal of histologically benign intracranial meningioma: late recurrence rate and factors predicting recurrence in 657 patients. A multivariate analysis. , 1986, Surgical neurology.
[25] G. Hanks,et al. The Value of Radiation Therapy as an Adjuvant to Surgery in Intracranial Meningiomas , 1986, American journal of clinical oncology.
[26] H. Whitwell,et al. Recurrence of meningiomas after operation. , 1986, Surgical neurology.
[27] J. Villemure,et al. Regulation of DNA synthesis and growth of cells derived from primary human meningiomas. , 1986, Cancer research.
[28] L. Kun,et al. Radiation therapy for incompletely resected meningiomas. , 1985, Journal of neurosurgery.
[29] Michael S. B. Edwards,et al. 5-Fluorouracil and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) followed by hydroxyurea, misonidazole, and irradiation for brain stem gliomas: a pilot study of the Brain Tumor Research Center and the Childrens Cancer Group. , 1984, Neurosurgery.
[30] V. Dolenc. Direct microsurgical repair of intracavernous vascular lesions. , 1983, Journal of neurosurgery.
[31] M. Blankenstein,et al. Presence of progesterone receptors and absence of oestrogen receptors in human intracranial meningioma cytosols. , 1983, European journal of cancer & clinical oncology.
[32] C Nicolini,et al. A comparison of mathematical methods for the analysis of DNA histograms obtained by flow cytometry , 1982, Cell and tissue kinetics.
[33] J. Annegers,et al. THE INCIDENCE OF PRIMARY INTRACRANIAL NEOPLASMS IN ROCHESTER, MINNESOTA, 1935‐1977 * , 1982, Annals of the New York Academy of Sciences.
[34] R. Herken,et al. Investigation of the effect of hydroxyurea on the cell cycle and the development of necrosis in the embryonic CNS of mice. , 1978, Teratology.
[35] B. Kennedy,et al. Hydroxyurea therapy in chronic myelogenous leukemia , 1972, Cancer.
[36] F. Rosner,et al. Studies on the absorption, distribution, and excretion of hydroxyurea (NSC-32065). , 1971, Cancer chemotherapy reports.
[37] R. Deconti,et al. Clinical and biochemical studies of high-dose intermittent therapy of solid tumors with hydroxyurea (NSC-32065). , 1970, Cancer chemotherapy reports.
[38] M. Rajewsky,et al. Synchronisation in vivo: kinetics of a malignant cell system following temporary inhibition of DNA synthesis with hydroxyurea. , 1970, Experimental cell research.
[39] I. Ariel. Therapeutic effects of hydroxyurea. Experience with 118 patients with inoperable solid tumors , 1970, Cancer.
[40] H. Elford. Effect of hydroxyurea on ribonucleotide reductase. , 1968, Biochemical and biophysical research communications.
[41] P. Reichard,et al. Inhibition of ribonucleoside diphosphate reductase by hydroxyurea. , 1968, Cancer research.
[42] A. Perez,et al. Action of hydroxyurea on the nucleic acid metabolism and viability of HeLa cells. , 1967, Cancer research.
[43] G. Schochetman,et al. Inhibition of DNA synthesis by hydroxyurea: structure-activity relationships. , 1967, Cancer research.
[44] B. Kennedy,et al. Metabolic and therapeutic effects of hydroxyurea in chronic myeloid leukemia. , 1966, JAMA.
[45] W. K. Sinclair. Hydroxyurea: Differential Lethal Effects on Cultured Mammalian Cells during the Cell Cycle , 1965, Science.
[46] H. Lerner,et al. Hydroxyurea (NSC-32065) in biologic fluids: dose-concentration relationship. , 1965, Cancer chemotherapy reports.
[47] B. Kennedy,et al. Hydroxyurea inhibition of DNA synthesis in ascites tumor. , 1965, Proceedings of the National Academy of Sciences of the United States of America.
[48] Bolton Bh,et al. A SIMPLE METHOD OF COLORIMETRIC ANALYSIS FOR HYDROXYUREA (NSC-32065). , 1965 .
[49] E. Freireich,et al. Clinical trials of hydroxyurea in patients with cancer and leukemia , 1964, Clinical pharmacology and therapeutics.
[50] M. Murphy,et al. PHASE II STUDIES OF HYDROXYUREA (NSC-32065) IN ADULTS: CLINICAL EVALUATION. , 1964, Cancer chemotherapy reports.
[51] Bloedow Ce. PHASE II STUDIES OF HYDROXYUREA (NSC-32065) IN ADULTS: MISCELLANEOUS TUMORS. , 1964 .
[52] W. C. Levin,et al. A phase I study of hydroxyurea. , 1963, Cancer chemotherapy reports.
[53] K. Losee,et al. HYDROXYUREA. A NEW TYPE OF POTENTIAL ANTITUMOR AGENT. , 1963, Journal of medicinal chemistry.
[54] Davidson Jd,et al. A method of analyzing for hydroxyurea in biological fluids. , 1963 .
[55] J. Suzuki,et al. A statistical study of brain tumors in the neurosurgical clinics in Japan. , 1959, Journal of neurosurgery.
[56] D. Simpson. THE RECURRENCE OF INTRACRANIAL MENINGIOMAS AFTER SURGICAL TREATMENT , 1957, Journal of neurology, neurosurgery, and psychiatry.
[57] J. Jääskeläinen,et al. Factors affecting operative and excess long-term mortality in 935 patients with intracranial meningioma. , 1992, Neurosurgery.
[58] A. Hagemeijer,et al. Inhibition of the growth of cultured human meningioma cells by recombinant interferon-alpha. , 1991, European journal of cancer.
[59] M. Nistér,et al. Expression of PDGF beta-receptors in human meningioma cells. , 1990, International journal of cancer.
[60] I. Bassukas,et al. An in vivo study on the synchronizing effect of hydroxyurea. , 1988, Experimental cell research.
[61] K. Zülch. Tumors of Meningeal and Related Tissues , 1986 .
[62] A. Wyllie. The biology of cell death in tumours. , 1985, Anticancer research.
[63] R. Chan,et al. Morbidity, mortality, and quality of life following surgery for intracranial meningiomas. A retrospective study in 257 cases. , 1984, Journal of neurosurgery.
[64] M. Khan,et al. The recurrence of intracranial meningiomas after surgical treatment. , 1983, Journal of neurosurgery.
[65] W. B. Butler,et al. Effects of serum and insulin on the sensitivity of the human breast cancer cell line MCF-7 to estrogen and antiestrogens. , 1981, Cancer research.
[66] A. Buge,et al. [Estrogen and progestin receptors in meningiomas: a study in 22 cases (author's transl)]. , 1980, Revue neurologique.
[67] Audrey M. Glauert,et al. Fixation, dehydration and embedding of biological specimens , 1975 .
[68] R. Livingston,et al. Single Agents in Cancer Chemotherapy , 1970, Springer US.
[69] L. A. Woods,et al. A SIMPLE METHOD OF COLORIMETRIC ANALYSIS FOR HYDROXYUREA (NSC-32065). , 1965, Cancer chemotherapy reports.
[70] C. Bloedow. PHASE II STUDIES OF HYDROXYUREA (NSC-32065) IN ADULTS: MISCELLANEOUS TUMORS. , 1964, Cancer chemotherapy reports.
[71] J. D. Davidson,et al. A method of analyzing for hydroxyurea in biological fluids. , 1963, Cancer chemotherapy reports.